ArticleAmerican journal of translational research2020

Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers might be associated with lung adenocarcinoma risk: a nationwide population-based nested case-control study.

Han-Lin Hsu et al.PubMed ↗Full text ↗

No numbers read from the abstract.